- Home
- RNTX vs WFF Comparison
RNTX vs WFF Comparison
Compare RNTX & WFF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- WFF
- Stock Information
- Founded
- RNTX 2001
- WFF 1984
- Country
- RNTX United States
- WFF Malaysia
- Employees
- RNTX N/A
- WFF N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- WFF Miscellaneous manufacturing industries
- Sector
- RNTX Health Care
- WFF Consumer Discretionary
- Exchange
- RNTX Nasdaq
- WFF Nasdaq
- Market Cap
- RNTX 40.3M
- WFF 44.1M
- IPO Year
- RNTX N/A
- WFF 2025
- Fundamental
- Price
- RNTX $1.16
- WFF $0.95
- Analyst Decision
- RNTX
- WFF
- Analyst Count
- RNTX 0
- WFF 0
- Target Price
- RNTX N/A
- WFF N/A
- AVG Volume (30 Days)
- RNTX 56.1K
- WFF 667.4K
- Earning Date
- RNTX 08-13-2025
- WFF 01-01-0001
- Dividend Yield
- RNTX N/A
- WFF N/A
- EPS Growth
- RNTX N/A
- WFF N/A
- EPS
- RNTX N/A
- WFF 0.00
- Revenue
- RNTX N/A
- WFF $4,572,290.00
- Revenue This Year
- RNTX N/A
- WFF N/A
- Revenue Next Year
- RNTX N/A
- WFF N/A
- P/E Ratio
- RNTX N/A
- WFF $193.34
- Revenue Growth
- RNTX N/A
- WFF N/A
- 52 Week Low
- RNTX $1.04
- WFF $0.81
- 52 Week High
- RNTX $4.40
- WFF $29.26
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- WFF N/A
- Support Level
- RNTX N/A
- WFF N/A
- Resistance Level
- RNTX N/A
- WFF N/A
- Average True Range (ATR)
- RNTX 0.00
- WFF 0.00
- MACD
- RNTX 0.00
- WFF 0.00
- Stochastic Oscillator
- RNTX 0.00
- WFF 0.00
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.